普蕊斯 reported revenue of ¥0.37B for the period ended 2026-06-30, -4.5% year on year. Net income was ¥0.00B, a 0.7% net margin on a 10.3% gross margin. The largest revenue line is SMO业务 at 100% of the total. Free cash flow for the period was ¥-0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.37B | -4.5% |
| Gross profit | ¥0.04B | — |
| Operating income | ¥0.00B | — |
| Net income | ¥0.00B | -95.2% |
| Gross margin | 10.3% | Net margin 0.7% |
| Revenue Q/Q | -8.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| SMO业务 | ¥0.37B | 99.7% |
| CRO业务 | ¥0.00B | 0.3% |
| 其他(补充) | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.33B | 89.7% |
| R&D | ¥0.02B | 5.1% |
| SG&A | ¥0.03B | 7.3% |
| Tax & other | ¥0.00B | 0.4% |
| Item | Amount |
|---|---|
| Total assets | ¥1.53B |
| Total liabilities | ¥0.26B |
| Shareholders' equity | ¥1.27B |
| Equity / assets | 82.7% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.00B |
| Cash conversion (OCF / net income) | -1177% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
富士莱 ・ 艾布鲁 ・ 格力博 ・ 恒工精密 ・ 海看股份 ・ 泰恩康 ・ 华新科技 ・ 宇邦新材 ・ 华厦眼科 ・ 铭利达 ・ 汉仪股份 ・ 英华特
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies